• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,370
2,300
1,860
1,850
1,725

COUNTRY

867
650
270
253
211

CATEGORIES

  • 858
  • 186
  • 679
  • 1,126
  • 391
  • 270
  • 252
  • 65
  • 378
  • 693
  • 1,330
  • 1,355
  • 625
  • 884
  • 1,695
  • 2,677
  • 507
  • 732
  • 0
  • 93

PRICE

6,792
11,418
17,941
25,150

PUBLISHED

1,984
2,685
7,337
25,150

PRODUCT TYPE

21,027
2,901
871
164
75
44
21
21
19
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

Degenerative Disc Disease - Pipeline Review, H1 2013

Degenerative Disc Disease - Pipeline Review, H1 2013 Summary 'Degenerative Disc Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

June 2013
FROM

Nebilet (Chronic Heart Failure) - Forecast and Market Analysis to 2022

Nebilet (Chronic Heart Failure) - Forecast and Market Analysis to 2022 Summary The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded...

June 2013
FROM

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM
Top ICT spenders in the UK Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013 Top ICT spenders in the UK Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013 - Product Thumbnail Image

Top ICT spenders in the UK Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013

Synopsis This report illustrates how Kable expects the top ICT spenders in the UK Pharmaceutical Industry to allocate their ICT budgets across the core areas of enterprise ICT spend, namely hardware,...

June 2013
FROM
The World Generic Market Report 2013 (Volume 1 & 2) The World Generic Market Report 2013 (Volume 1 & 2) - Product Thumbnail Image

The World Generic Market Report 2013 (Volume 1 & 2)

A Complete Global Analysis Of The Prospects For Markets And Companies In This Dynamic Industry Sector Features and benefits of this thoroughly-researched and highly-regarded management report: - High...

June 2013
FROM

Critical Care Manual of Clinical Procedures and Competencies

This manual is aimed at all healthcare practitioners, from novice to expert, who care for the critically ill patient, recognising that different disciplines contribute to the provision of effective...

June 2013

Esophageal Cancer - Pipeline Review, H1 2013

'Esophageal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Esophageal Cancer, complete...

June 2013
FROM

Critical Limb Ischemia - Pipeline Review, H1 2013

'Critical Limb Ischemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Critical Limb Ischemia,...

June 2013
FROM

Inflammation - Pipeline Review, H1 2013

Inflammation – Pipeline Review, H1 2013 Summary 'Inflammation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic...

June 2013
FROM

Japanese Encephalitis - Pipeline Review, H1 2013

Japanese Encephalitis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Japanese Encephalitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

June 2013
FROM

Carcinomas - Pipeline Review, H1 2013

Carcinomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

June 2013
FROM

Cognitive Disorders - Pipeline Review, H1 2013

Cognitive Disorders – Pipeline Review, H1 2013 Summary 'Cognitive Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information...

June 2013
FROM

Post-Operative Pain - Pipeline Review, H1 2013

Post-Operative Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Post-Operative Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

June 2013
FROM

Anxiety Disorders - Pipeline Review, H1 2013

Anxiety Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Anxiety Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

June 2013
FROM

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2013

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H1 2013 Summary 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2013', provides an overview of the indication's...

June 2013
FROM

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2013

H5N1 Infection (Avian Influenza) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2013', provides an overview of the indication’s...

June 2013
FROM

Thrombosis - Pipeline Review, H1 2013

Thrombosis – Pipeline Review, H1 2013 Summary 'Thrombosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic...

June 2013
FROM

Ageing - Pipeline Review, H1 2013

Ageing – Pipeline Review, H1 2013 Summary 'Ageing - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

June 2013
FROM

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2013

'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

June 2013
FROM
Loading Indicator

Our Clients

Our clients' logos